BLAINTRAVENOUS, SUBCUTANEOUSSOLUTION2 Generics Approved
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
18
Data completeness
5/8 — Partial
FIASP (insulin aspart injection) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIASP (insulin aspart injection) is a rapid-acting insulin analog manufactured by Novo Nordisk, approved by the FDA on September 29, 2017. It is indicated for the treatment of diabetes mellitus and works by mimicking the body's natural insulin response to regulate blood glucose. FIASP is administered via subcutaneous or intravenous injection and represents an advancement in mealtime insulin therapy with faster onset compared to standard insulin aspart formulations.
$0.0BPart D
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®
Started Mar 2022
240 enrolled
Type 1 Diabetes
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
Started Oct 2021
411 enrolled
Diabetes Mellitus, Type 1
An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
Started Jan 2021
42 enrolled
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Started Dec 2020
137 enrolled
Type 2 Diabetes Treated With Insulin
Effect of Fiasp® in Type 1 Diabetes Treatment
Started Jan 2020
178 enrolled
Diabetes Mellitus, Type 1
Worked on FIASP at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.